Read by QxMD icon Read

treatment of hepatocellular carcinoma

Hong Zhu, Xiaojun Ma, Yaqin Zhao, Ji Duo
RATIONALE: Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sorafenib treatment or patients who are intolerant of sorafenib remain an unmet medical need. PATIENT CONCERNS: We report an advanced HCC patient with many lung metastases who failed sorafenib treatment...
June 2018: Medicine (Baltimore)
Huan He, Xin-Yue Shang, Wei-Wei Liu, Yan Zhang, Shao-Jiang Song
The fruit of Camptotheca acuminata, a kind of mainly medicinal plant, possesses good antitumor properties. In order to explore the bioactive compounds for the treatment of hepatocellular carcinoma, the study focused on the isolation of cytotoxic compounds from the fruit of Camptotheca acuminata, which led to the discovery of fourteen compounds, including one new triterpene, 3β,20-dihydroxy-30α-methyl,17(29)-β-epoxy-28-norlupane (1), together with thirteen known compounds (2-14). The structures of isolated compounds were demonstrated by spectroscopic methods including 1D and 2D NMR spectroscopy...
June 20, 2018: Natural Product Research
Guoju Hong, Vincent Kuek, Jiaxi Shi, Lin Zhou, Xiaorui Han, Wei He, Jennifer Tickner, Heng Qiu, Qiushi Wei, Jiake Xu
Epidermal growth factor-like domain-containing protein 7 (EGFL7), a member of the epidermal growth factor (EGF)-like protein family, is a potent angiogenic factor expressed in many different cell types. EGFL7 plays a vital role in controlling vascular angiogenesis during embryogenesis, organogenesis, and maintaining skeletal homeostasis. It regulates cellular functions by mediating the main signaling pathways (Notch, integrin) and EGF receptor cascades. Accumulating evidence suggests that Egfl7 plays a crucial role in cancer biology by modulating tumor angiogenesis, metastasis, and invasion...
June 19, 2018: Journal of Cellular Physiology
Li-Fang Wu, Sheng-Xiang Rao, Peng-Ju Xu, Li Yang, Cai-Zhong Chen, Hao Liu, Jian-Feng Huang, Cai-Xia Fu, Alice Halim, Meng-Su Zeng
PURPOSE: To determine the feasibility of pre-TACE IVIM imaging based on histogram analysis for predicting prognosis in the treatment of unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Fifty-five patients prospectively underwent 1.5T MRI 1 week before TACE. Histogram metrics for IVIM parameters and ADCs maps between responders and non-responders with mRECIST assessment were compared. Kaplan-Meier, log-rank tests and Cox proportional hazard regression model were used to correlate variables with time to progression (TTP)...
June 19, 2018: European Radiology
Jinghua Peng
Inflammation contributes heavily to the pathogenesis of liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Inflammation is probably a promising target for treatment of liver diseases. The natural products are considered as the potential source of new drug discovery and their pharmacological effects on hepatic inflammation have been widely reported. In this review, the natural products with anti-hepatic inflammatory properties are summarized based on their pharmacological effects and mechanisms, which are related to the suppression on the inflammation mediators including cytokines and chemokines, pattern recognition receptors, the activated transcriptional factors, and the potential regulatory factors...
2018: Frontiers in Pharmacology
Jin Chen, Zhao-Qi Zhang, Jia Song, Qiu-Meng Liu, Chao Wang, Zhao Huang, Liang Chu, Hui-Fang Liang, Bi-Xiang Zhang, Xiao-Ping Chen
18β-Glycyrrhetinic acid (GA) is the active ingredient of the traditional Chinese medicine, Glycyrrhrzae Radix et Rhizoma. Here, we explored the effects of GA on hepatocellular carcinoma (HCC) in vitro and in vivo and the underlying molecular mechanisms. We confirmed that GA suppressed proliferation of various HCC cell lines. Treatment of GA caused G0/G1 arrest, apoptosis and autophagy in HCC cells. GA-induced apoptosis and autophagy were mainly due to the unfolded protein response. We compared the roles of the ATF4/CHOP and IRE1α/XBP1s UPR pathways, which were both induced by GA...
June 19, 2018: Scientific Reports
A Loglio, M Iavarone, G Grossi, M Viganò, M G Rumi, F Facchetti, G Lunghi, A Sangiovanni, M Colombo, P Lampertico
BACKGROUND: Long-term oral nucleos(t)ide analogue (NUC) therapy in hepatitis B virus (HBV)-related compensated cirrhotics prevents clinical decompensation but not hepatocellular carcinoma (HCC) development. AIMS: To define the clinical features and outcomes of HCC in long-term NUC-treated HBV patients. METHODS: All HCCs developing between 2005 and 2016 in NUC-treated HBV patients under surveillance were studied, excluding those that occurred within the first 6 months of therapy...
June 19, 2018: Alimentary Pharmacology & Therapeutics
Kunichika Matsumoto, Yinghui Wu, Takefumi Kitazawa, Shigeru Fujita, Kanako Seto, Tomonori Hasegawa
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth leading cause of death in Japan. The aim of this study was to calculate the social burden of HCC using the cost of illness (COI) method, and to identify the key factors driving changes in the economic burden of HCC. METHODS: Utilizing government-based statistical nationwide data, the cost of illness (COI) method was used to estimate the COI for 1996, 1999, 2002, 2005, 2008, and 2014 to make predictions for 2017, 2020, 2023, 2026, and 2029...
2018: PloS One
Xiaowei Diao, Xiubin Chen, Yurui Pi, Yu Zhang, Fangfang Wang, Ping Liu, Yanhong Gao, Xiaojun Wang, Sijun Yang, Shan Lu
Erythropoietin‑producing hepatocellular carcinoma cell surface type‑A receptor 3 (EPHA3) has been found to promote the proliferation and survival of prostate cancer (PCa) cell lines and prostate tumor development in nude mice. However, the regulation of EPHA3 in PCa remains largely unknown. This study is aimed to investigate the association between EPHA3 expression and androgen receptor (AR) signaling and the potential mechanism. We determined mRNA and protein levels of EPHA3 and AR signaling‑related genes in the PCa cell line 22Rv1 by reverse transcription‑polymerase chain reaction (RT‑PCR) and western blotting, respectively...
June 18, 2018: Oncology Reports
Kyoung Doo Song, Min Woo Lee, Hyunchul Rhim, Tae Wook Kang, Dong Ik Cha, Dong Hyun Sinn, Hyo Keun Lim
Purpose To evaluate the technical feasibility and therapeutic outcomes of percutaneous US/MRI fusion-guided radiofrequency ablation (RFA) of recurrent subcentimeter-sized hepatocellular carcinomas (HCCs). Materials and Methods For this retrospective study, between January 2012 and December 2014 a total of 194 planning US examinations were performed in 186 patients (159 men and 27 women; mean age, 61.1 years ± 10.0 [standard deviation]) for newly developed subcentimeter recurrent HCCs. These recurrent HCCs were defined as hypervascular nodules (>5...
June 19, 2018: Radiology
Xue Jing, Zibin Tian, Pujun Gao, Huashi Xiao, Xiaolong Qi, Yanan Yu, Xueli Ding, Lin Yang, Liang Zong
Chronic hepatitis B virus (HBV) infection remains one of the leading causes of hepatocellular carcinoma (HCC) globally. However, the mechanism underlying the mediation by HBV surface proteins (HBsAgs) of the early steps in the virus life cycle and following HCC development is unclear. β‑2‑glycoprotein I (β2GPI) specifically interacts with HBsAg and demonstrates high expression during the earliest stages of hepatitis B virus infection. In the present study, the assessment of HCC and adjacent tissues revealed that the levels of mRNA and protein of β2GPI were highly expressed in HBV‑related HCC...
June 19, 2018: Oncology Reports
Xiaolong Tang, Longzhou Chen, Amin Li, Shiyu Cai, Yinci Zhang, Xueke Liu, Zhenyou Jiang, Xinkuang Liu, Yong Liang, Dong Ma
Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific targeting, the concentration of the drug in tumor tissue cannot be permanently maintained at a level that inhibits tumor growth. To overcome this problem, we developed a novel SFB-loaded polymer nanoparticle (NP). The NP (a TPGS-b-PCL copolymer that was synthesized from ε-caprolactone and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) via ring-opening polymerization) contains Pluronic P123 and SFB, and its surface is modified with anti-GPC3 antibody to produce the polymer nanoparticle (NP-SFB-Ab)...
November 2018: Drug Delivery
Norio Kubo, Norifumi Harimoto, Kei Shibuya, Norihiro Ishii, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Kenichiro Araki, Masaya Miyazaki, Hiroyuki Kuwano, Ken Shirabe
BACKGROUND: Bile leakage after hepatectomy still causes relatively serious problems, and some types of bile leakage are intractable. CASE PRESENTATION: We report a case of postoperative isolated bile duct leakage managed successfully by combination therapy of percutaneous transhepatic portal vein embolization (PTPE) and bile duct ablation with ethanol. A 61-year-old man diagnosed with hepatocellular carcinoma underwent partial hepatectomy. On postoperative day 1, bile leakage was detected at the drainage tube...
June 19, 2018: Surgical Case Reports
Young-A Heo, Yahiya Y Syed
Regorafenib (Stivarga® ), a small molecule inhibitor of multiple kinases, is the first drug to be approved for the treatment of hepatocellular carcinoma (HCC) in patients who have progressed during or after sorafenib therapy. Its approval was based on the results of the randomized, double-blind, placebo-controlled, multinational, phase III RESORCE trial in patients with HCC who had progressed during sorafenib therapy. In RESORCE, regorafenib significantly prolonged overall survival (OS; primary endpoint), progression-free survival (PFS) and time to progression (TTP) compared with placebo, with the OS benefit appearing to be largely due to disease stabilization...
June 18, 2018: Drugs
Megan Sue Soliman, Youssef Yousry Soliman, Qamar Ahmad, Roopa Yarlagadda
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is the third highest cause of cancer mortality worldwide. Risk factors include chronic liver disease and cirrhosis of various causes including chronic hepatitis B and C. In cases of chronic hepatitis C virus (HCV), HCC usually does not manifest unless the liver has become cirrhotic. Fortunately, novel treatments for hepatitis C including ledipasvir/sofosbuvir can cure patients from their disease and as a result, may never develop cirrhosis and therefore, be at much lower risk of developing HCC...
2018: Journal of Community Hospital Internal Medicine Perspectives
Chao-Yuan Huang, Man-Hsin Hung, Chi-Ting Shih, Feng-Shu Hsieh, Chiung-Wen Kuo, Ming-Hsien Tsai, Shih-Shin Chang, Yung-Jen Hsiao, Li-Ju Chen, Tzu-I Chao, Kuen-Feng Chen
Increasing evidence suggests that SET functions as an oncoprotein and promotes cancer survival and therapeutic resistance. However, whether SET affects radiotherapy (RT)-mediated anti-cancer effects has not yet been explored. Here, we investigated the impact of SET on RT sensitivity in hepatocellular carcinoma (HCC). Using colony and hepatosphere formation assay, we found that RT-induced proliferative inhibition was critically associated with SET expression. Next, we tested a novel SET antagonist, EMQA, in combination with RT...
June 18, 2018: Journal of Pharmacology and Experimental Therapeutics
Hongying Liu, Xieqi Wang, Bing Feng, Lipeng Tang, Weiping Li, Xirun Zheng, Ying Liu, Yan Peng, Guangjuan Zheng, Qinglian He
BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related deaths worldwide. Despite new technologies in diagnosis and treatment, the incidence and mortality of HCC continue rising. And its pathogenesis is still unclear. As a highly conserved protein of the Golgi apparatus, Golgi phosphoprotein 3 (GOLPH3) has been shown to be involved in tumorigenesis of HCC. This study aimed to explore the exact oncogenic mechanism of GOLPH3 and provide a novel diagnose biomarker and therapeutic strategy for patients with HCC...
June 18, 2018: BMC Cancer
Guan-Hui Zhou, Jun Han, Jun-Hui Sun, Yue-Lin Zhang, Tan-Yang Zhou, Chun-Hui Nie, Tong-Yin Zhu, Sheng-Qun Chen, Bao-Quan Wang, Zi-Niu Yu, Hong-Liang Wang, Li-Ming Chen, Wei-Lin Wang, Shu-Sen Zheng
BACKGROUND: This study aimed to investigate the efficacy and safety of drug eluting beads transarterial chemoembolization (DEB-TACE) treatment by CalliSpheres® in Chinese patients with hepatocellular carcinoma (HCC) as well as the predicting factors for response. METHODS: 99 patients with HCC were consecutively enrolled in this study. All participants were treated by CalliSpheres® DEB-TACE. Clinical response was evaluated according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria...
June 8, 2018: BMC Cancer
Shun Yamamoto, Shunsuke Kondo
Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). However, few agents have shown efficacy. It is thought that the efficacy of some agents might have resulted from the heterogeneity of tumors, insufficient dosages due to liver cirrhosis, and post-therapy effects. In recent years, immune checkpoint inhibitors have shown promising clinical activity and safety in patients with advanced HCC. Areas covered: The authors provide an overview of chemotherapies used for the treatment of HCC, including ongoing trials...
June 18, 2018: Expert Opinion on Pharmacotherapy
Hitomi Takada, Masayuki Kurosaki, Hiroyuki Nakanishi, Yuka Takahashi, Jun Itakura, Kaoru Tsuchiya, Yutaka Yasui, Nobuharu Tamaki, Kenta Takaura, Yasuyuki Komiyama, Mayu Higuchi, Youhei Kubota, Wann Wang, Mao Okada, Nobuyuki Enomoto, Namiki Izumi
BACKGROUND: The present study aimed to investigate the impact of pre-sarcopenia on the prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS: We enrolled 214 patients (71 ± 10 years old; 166 men and 48 women; 90% Child-Pugh grade A and 10% Child-Pugh grade B) treated with sorafenib in our hospital from July 2009 to August 2016. The muscle volume was measured from CT images just before sorafenib administration using software (SliceOmatic)...
2018: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"